MedTrace Logo

Alternate Donor Study of Pre-Emptive Cellular Therapy

NCT01220895 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2018-01-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the potential clinical benefit of pre-emptive cytomegalovirus (CMV)-specific adoptive cellular therapy following T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) for reducing recurrent CMV reactivation.

Conditions

  • Cytomegalovirus Infection

Interventions

BIOLOGICAL

CMV-specific T-cells, single infusion following single positive CMV PCR result

1. Intravenous ganciclovir 5mg/kg twice daily 2. Oral valganciclovir 900mg twice daily 3. Intravenous foscarnet 90 mg/kg twice daily

Sponsors & Collaborators

  • Leukaemia Lymphoma Research

    collaborator OTHER

  • National Health Service, Blood and Transplant

    collaborator UNKNOWN

  • University of Birmingham

    collaborator OTHER

  • Cell Medica Ltd

    lead INDUSTRY

Principal Investigators

  • Karl S Peggs · University College London Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-12-31
Completion
2014-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01220895 on ClinicalTrials.gov